Mitchell Machtay, MD | Authors

PORTable Indications in Non–Small-Cell Lung Carcinoma

March 01, 2008

Drs. Kelsey, Marks, and Wilson open their excellent review article by asking “Where do we stand?” with respect to postoperative radiation therapy (PORT) for non–small-cell lung cancer (NSCLC).[1] Frankly, PORT has not exactly been standing tall for the past decade-leaning, crouching, or perhaps squatting might be a better verb.

Role of Adjuvant Therapy in Resected Stage II/IIIA Non-Small-Cell Lung Cancer

January 01, 2002

Dr. Movsas has written a thorough, accurate description of the state of the art on postoperative, adjuvant therapy for resected "high risk" non-small-cell lung carcinoma (NSCLC). Management of this common situation indeed remains an "art," since the results of "scientific" randomized trials have been singularly disappointing.

Commentary (Machtay)-Anemia Treatment and the Radiation Oncologist: Optimizing Patient Outcomes

November 01, 2001

Anemia is a frequent complication of cancer and its associated treatment. Although its occurrence is well documented in the chemotherapy setting, the prevalence and nature of anemia in the radiation oncology setting